A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Abuse, Drug

Interventions

DRUG: Cebranopadol- 600 ug
DRUG: Cebranopadol- 800ug
DRUG: Cebranopadol- 1000ug
DRUG: Treatment A:
DRUG: Treatment B
DRUG: Treatment C
DRUG: Qualification
DRUG: Qualification

Sponsor

Tris Pharma, Inc.

Collaborators

[object Object]